Clinical Efficacy of Tangning Tongluo Tablets for Nonproliferative Diabetic Retinopathy
10.13422/j.cnki.syfjx.20242094
- VernacularTitle:糖宁通络片治疗非增殖期糖尿病视网膜病变的临床疗效
- Author:
Fuwen ZHANG
1
;
Junguo DUAN
1
;
Wen XIA
2
;
Tiantian SUN
2
;
Yuheng SHI
3
;
Shicui MEI
3
;
Xiangxia LUO
4
;
Xing LI
2
;
Yujie PAN
2
;
Yong DENG
5
;
Chuanlian RAN
1
;
Hao CHEN
1
;
Li PEI
1
;
Shuyu YANG
6
Author Information
1. Eye School/Ineye Hospital，Chengdu University of Traditional Chinese Medicine（TCM），Chengdu 610075，China
2. Guizhou Bailing Enterprise Group Pharmaceutical Co. Ltd.，Anshun 561000，China
3. The Second Affiliated Hospital of Guizhou University of TCM，Guiyang 550003，China
4. The First Affiliated Hospital of Gansu University of Chinese Medicine，Lanzhou 730000，China
5. Anshun People's Hospital of Guizhou Province，Anshun 561099，China
6. School of Medicine，Xiamen University，Xiamen 361003，China
- Publication Type:Journal Article
- Keywords:
diabetic retinopathy;
traditional Chinese medicine;
clinical efficacy;
Tangning Tongluo tablets;
vision
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(3):132-139
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the clinical efficacy and safety of Tangning Tongluo tablets in the treatment of nonproliferative diabetic retinopathy （DR）. MethodsFourteen research centers participated in this study， which spanned a time interval from September 2021 to May 2023. A total of 240 patients with nonproliferative DR were included and randomly assigned into an observation group （120 cases） and a control group （120 cases）. The observation group was treated with Tangning Tongluo tablets， and the control group with calcium dobesilate capsules. Both groups were treated for 24 consecutive weeks. The vision， DR progression rate， retinal microhemangioma， hemorrhage area， exudation area， glycosylated hemoglobin （HbA1c） level， and TCM syndrome score were assessed before and after treatment， and the safety was observed. ResultsThe vision changed in both groups after treatment （P<0.05）， and the observation group showed higher best corrected visual acuity （BCVA） than the control group （P<0.05）. The DR progression was slow with similar rates in the two groups. The fundus hemorrhage area and exudation area did not change significantly after treatment in both groups， while the observation group outperformed the control group in reducing the fundus hemorrhage area and exudation area. There was no significant difference in the number of microhemangiomas between the two groups before treatment. After treatment， the number of microhemangiomas decreased in both the observation group （Z=-1.437， P<0.05） and the control group （Z=-2.238， P<0.05）， and it showed no significant difference between the two groups. As the treatment time prolonged， the number of microhemangiomas gradually decreased in both groups. There was no significant difference in the HbA1c level between the two groups before treatment. After treatment， the decline in the HbA1c level showed no significant difference between the two groups. The TCM syndrome score did not have a statistically significant difference between the two groups before treatment. After treatment， neither the TCM syndrome score nor the response rate had significant difference between the two groups. With the extension of the treatment time， both groups showed amelioration of TCM syndrome compared with the baseline. ConclusionTangning Tongluo tablets are safe and effective in the treatment of nonproliferative DR， being capable of improving vision and reducing hemorrhage and exudation in the fundus.
